Ibrutinib and Acalabrutinib Use and Risk of Atrial Fibrillation in Patients With Chronic B-cell Malignancies
Active, not recruiting
- Conditions
- Chronic B-cell MalignanciesBTK InhibitorsCardiovascular Diseases
- Registration Number
- NCT06561243
- Lead Sponsor
- University Hospital, Caen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Active, not recruiting
- Sex
- All
- Target Recruitment
- 15000
Inclusion Criteria
Inclusion Criteria:<br><br> - adult patients<br><br> - diagnose with chronic B-cell malignancies using ICD-10-CM codes C91 (lymphoid<br> leukemia), C88.0 (Waldenström macroglobulinemia), C83.1 (mantle cell lymphoma),<br> C81-C96 (malignant neoplasms of lymphoid, hematopoietic and related tissue) or C95<br> (leukemia of unspecified cell type)<br><br> - expose to ibrutinib or acalabrutinib determined by the Anatomical Therapeutic<br> Chemical codes<br><br>Exclusion Criteria:<br><br>
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Risk of incident atrial fibrillation in patients exposed to ibrutinib compared with those exposed to acalabrutinib in the whole matched cohort.
- Secondary Outcome Measures
Name Time Method